AI Terminal
ALLERGY THERAPEUTICS PLC
Regulatory Filings • May 21, 2019
7477_rns_2019-05-21_95ec3c5c-aec0-4a5c-a272-4e548564e8b8.html
Regulatory Filings
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
Hardman & Co Research
Hardman & Co Research: Allergy Therapeutics (AGY): House dust mite vaccine - clinical progress
21-May-2019 / 07:15 GMT/BST
Hardman & Co: House dust mite vaccine - clinical progress
AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. The Pollinex Quattro (PQ) platform, an ultra-short-course subcutaneous allergy immunotherapy (SCIT), continues to gain market share despite its availability in the EU on a 'named-patients' (NP) basis only. The aim of ongoing trials is to move the platform to full registration under the new regulatory framework. Following the success of 'Acarovac Plus' in NP, the 'Acarovac MPL' vaccine for house dust mite allergy is in clinical development to provide a registered vaccine. Results from the Phase I trial of Acarovac MPL were positive, demonstrating safety and tolerability.
Please click here for the full report:
https://www.hardmanandco.com/research/corporate-research/house-dust-mite-vaccine-clinical-progress/
| To contact us: Hardman & Co 35 New Broad Street London EC2M 1NH www.hardmanandco.com Follow us on Twitter @HardmanandCo |
Contacts: Dr Martin Hall Dr Dorothea Hill Dr Gregoire Pave +44 20 7194 7622 |
[email protected] [email protected] [email protected] |
Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.
About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the world with high-quality research, investor engagement programmes and advisory services.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.
Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service
813719 21-May-2019